Smoking cessation may deteriorate glycemic control in diabetic patients
the ONA take:
Patients with type 2 diabetes mellitus who quit smoking see a temporary deterioration in glycemic control that may last up to three years, according to a recent study published in The Lancet Diabetes & Endocrinology.
Researchers led by Deborah Lycett, PhD, of Convetry University studied primary care records of 10,692 adult smokers with type 2 diabetes mellitus over six years to see if there was any association between diabetes control and smoking cessation.
They found that in 3,131 people (29 percent) who had quit for at least one year, HbA1c increased by 2.3 mmol/mol before gradually decreasing as abstinence continued.
During the same amount of time, 5,831 (55 percent) of patients who continually smoked experienced a more gradual increase in HbA1c. Those who quit saw comparable HbA1c levels with continual smokers after three years of quitting.
“Knowing that deterioration in blood glucose control occurs around the time of stopping smoking helps to prepare those with diabetes and their clinicians to be proactive in tightening their glycemic control during this time,” Dr. Lycett concluded.
Patients with type 2 diabetes mellitus who quit smoking see a temporary deterioration in glycemic control that may last up to three years.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|